Former Lilly sales rep sues drugmaker over Mounjaro promotion
Jennifer Mansion says she saw colleagues repeatedly promote Mounjaro for weight loss, which is outside its FDA-approved indication for treating diabetes.
Eli Lilly and Co.
-
Lilly asks U.S. Supreme Court to rule part of False Claims Act unconstitutional
The Indianapolis-based drugmaker is challenging a $183.7 million judgment in a case brought by a pharmacist who alleged Lilly made false claims about rebates to the federal Medicaid program.
Read More -
RICO suit vs. Lilly could reap billions if successful
Lilly denies the claims, which are related to the labeling of a drug some 16 years ago, and has fought the use of so-called RICO statutes as the basis of the case.
Read More -
Federal Circuit tweaks statute to overcome constitutionality concerns with administrative patent judges
On Halloween 2019, a constitutional argument against the process for challenging patents not only convinced a federal appellate court but also inspired the judges to offer their own fix to the statute.
Read More
Articles
Judge won’t block Lilly ads for weight-loss drugs in ruling against Novo Nordisk
The dispute involves advertisements by Lilly for Zepbound and Mounjaro that claim the drugs are superior to Novo’s Wegovy and Ozempic.
Eli Lilly sued over stomach problems patient ties to Mounjaro and Trulicity
Patient Frank Campbell Jr. says in his lawsuit that Lilly didn’t do enough to warn about severe side effects that can come from its products.
Lilly fighting black market for its next obesity drug
On Aug. 12, Eli Lilly filed the first six lawsuits in its battle against the black market for its experimental weight-loss medication retatrutide.
Novo Nordisk sues Eli Lilly over ‘misleading’ GLP-1 advertisements
Novo argues that Eli Lilly’s advertisements for its GLP-1 drugs are “deliberately simple and deliberately false,” causing harm to both Novo and “the patients Lilly deceives.”
Florida hospital sues Lilly over move to suspend access to federal drug discount program
In the complaint, Tampa General Hospital calls Eli Lilly and Co.’s move “unconscionable and immoral.”
7th Circuit restores breach-of-contract case against Eli Lilly
The appellate court held that Teva plausibly alleged that Lilly breached the two companies’ 2018 settlement agreement, which stipulated that Lilly would not interfere with Teva getting approval for a generic version of Lilly’s osteoporosis drug, Forteo.
Lilly rebuffed by Supreme Court on $194M Medicaid award
The case against Lilly centered on the rebates that drug companies must pay to state Medicaid programs to subsidize some of the cost.
Fight over GLP-1 compounding plays out in statehouses, courthouses
Since 2023, Eli Lilly and Co. has filed lawsuits against dozens of compound pharmacies, weight-loss centers and health spas that produced and sold copies of Mounjaro and Zepbound.
Indiana attorney general sues Lilly over insulin prices
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
Texas AG: Eli Lilly and Co. offered kickbacks to providers to prescribe blockbuster drugs
Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe the Indianapolis-based company’s drugs including blockbuster GLP-1 medications Mounjaro and Zepbound, according to a recent lawsuit.
More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects
The lawsuits have been filed over the past two weeks in Marion Superior Court against Eli Lilly and Co., which says its drugs have been tested for safety and include robust, FDA-approved warnings.
Lilly sues Indianapolis clinic for selling split doses of popular weight-loss drugs
Eli Lilly and Co. is suing an Indianapolis-based weight-loss clinic it says is improperly selling Lilly’s hugely popular diabetes and weight-loss drugs.
LEAP spending nears $1B with projected budget shielded, investigation finds
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic development projects Indiana has attempted. But the agency’s structure obscures its spending and who benefits.
Medicaid coverage of weight-loss drugs could cost state up to $70 million a year
The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.
Amid backlash, FDA changes course over shortage of Lilly weight-loss drugs
The U.S. Food and Drug Administration, after intense public pressure and a lawsuit, is reconsidering its declaration barely two weeks ago that a shortage of the appetite-suppressing drugs Mounjaro and Zepbound—both made by Indianapolis-based Eli Lilly and Co.—is over, a temporary about-face that will allow pharmacies to keep selling unbranded copies.
Lilly weight-loss drug copycat makers sue FDA for taking drugs off shortage list
A group representing companies that made copycat versions of Eli Lilly and Co.’s weight-loss drugs has sued the U.S. Food and Drug Administration over the agency’s decision to remove Lilly’s medications from its shortage list.
Lilly files suit against more spas, weight-loss centers selling knockoff version of its popular drugs
Just one month after settling with a South Carolina medical spa that was selling knockoff versions of its popular diabetes and weight-loss drugs, Eli Lilly and Co. is going after other sellers.
Federal judge grants collective status in suit brought by Lilly worker who claimed age bias
The ruling potentially opens the door to hundreds of Lilly employees over 40 years old who have been denied promotions for which they feel they were qualified.
Nevada company sues Lilly for breach of contract over Alzheimer’s drug
A Nevada-based biotech company is suing Eli Lilly and Co., saying the Indianapolis-based drugmaker is refusing to pay royalties on patented technology it claims is used in Lilly’s pending new treatment for Alzheimer’s disease.